This edition of Q&A features Kalyan Vinnakota, Senior Scientific Program Manager who is helping us accelerate a cure for neurofibromatosis (NF1). He leads the Vision Restoration Initiative, comprised of a “dream team” of basic science and clinical researchers focused on developing viable therapies for NF patients suffering from optic nerve […]

For the first time, the Gilbert Family Foundation is excited to release our annual impact report. This 2022 report highlights the investments we've made and the programs we created in the past year, all of which support our mission to build opportunity and equity in Detroit and accelerate a cure […]

In our efforts to accelerate a cure for neurofibromatosis, we are proud to announce a $10M investment funding neurofibromatosis research at the Children's Hospital of Philadelphia (CHOP), which will support critical medical research via CHOP's Neurofibromatosis Program.

The Gilbert Family Foundation today announced $23 million in grants to fund research projects as part of the organization’s Vision Restoration Initiative (VRI) and Brain Tumor Initiative (BTI).

Recently, we brought together nine research teams for our first-ever in-person Gene Therapy Initiative Annual Meeting.

Our Vision Restoration Initiative (VRI) awardees and their teams convened for our VRI Annual Meeting to discuss the results of their research projects focused on vision restoration therapies. Watch the video to learn more about the event and their findings.

The Gilbert Family Foundation is excited to welcome 28 researchers to our 2022 Vision Restoration Initiative (VRI) annual meeting. We will be discussing the latest breakthroughs in neurofibromatosis type 1 (NF1) optic pathway glioma and vision restoration research.

The Gilbert Family Foundation is excited to announce a new round of three-year grants in the Gene Therapy Initiative to support the development of curative therapies that address the underlying cause of NF1.

Preclinical models provide a key role in developing treatments for neurofibromatosis type 1. The Gilbert Family Foundation not only supports projects that utilize available preclinical models, but projects that aim to expand these resources.

The Gilbert Family Foundation today announced funding of a new $5.4 million clinical study which aims to understand the mechanisms of vision loss caused by NF1-associated optic pathway gliomas, or NF1-OPGs.

The Gilbert Family Foundation today announced the launch of a clinical study that aims to validate optical coherence tomography (OCT) as a tool to objectively assess the visual system and its response to treatment in NF1 patients with optic pathway gliomas.

The Gilbert Family Foundation (GFF) is excited to announce the development of a database for neurofibromatosis type 1 (NF1) research tools in collaboration with Sage Bionetworks. The database aims to support the development of a robust NF1 research toolkit while also lowering the barrier of entry to research for new-to-NF1 […]